GSK Shares Rise on Positive Lung Cancer Drug Trial Data

Shares in British pharmaceutical giant GSK (LON:GSK) rose on Monday after the company reported positive clinical trial results for two separate lung cancer treatments, boosting investor confidence in its oncology pipeline.

Key Trial Results

GSK announced that its lung cancer drug, Jideytro, successfully achieved its primary endpoint in a recent trial. According to the company, the treatment demonstrated a 94% rate of complete or partial tumor shrinkage among patients participating in the study.

In a separate announcement, GSK reported positive late-stage trial data for Ris-Rez, a drug licensed from Hansoh Pharmaceutical (HK:3692). The study found that the treatment reduced the risk of death by 54% compared to standard chemotherapy in patients with relapsed small cell lung cancer.

Ad

Market Impact

Following the news, GSK's shares climbed 2.5% to 1,815 pence in London trading. The positive data provides a significant boost to the company's drug development pipeline, a key driver of value for pharmaceutical firms.

For investors, successful clinical trials are a critical milestone that de-risks a drug's path toward regulatory approval and commercialization. The strong efficacy data from both Jideytro and Ris-Rez signals the potential for new, significant revenue streams in the highly competitive oncology market.